7T97 image
Entry Detail
PDB ID:
7T97
Keywords:
Title:
Crystal structure of engineered CYS-CYS fab dimer CH1-207 (HC4)
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-12-18
Release Date:
2022-10-12
Method Details:
Experimental Method:
Resolution:
2.14 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:FAB Heavy chain
Chain IDs:A, C, E, G (auth: H)
Chain Length:228
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FAB Light Chain
Chain IDs:B, D, F, H (auth: L)
Chain Length:214
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Antibody interfaces revealed through structural mining.
Comput Struct Biotechnol J 20 4952 4968 (2022)
PMID: 36147680 DOI: 10.1016/j.csbj.2022.08.048

Abstact

Antibodies are fundamental effectors of humoral immunity, and have become a highly successful class of therapeutics. There is increasing evidence that antibodies utilize transient homotypic interactions to enhance function, and elucidation of such interactions can provide insights into their biology and new opportunities for their optimization as drugs. Yet the transitory nature of weak interactions makes them difficult to investigate. Capitalizing on their rich structural data and high conservation, we have characterized all the ways that antibody fragment antigen-binding (Fab) regions interact crystallographically. This approach led to the discovery of previously unrealized interfaces between antibodies. While diverse interactions exist, β-sheet dimers and variable-constant elbow dimers are recurrent motifs. Disulfide engineering enabled interactions to be trapped and investigated structurally and functionally, providing experimental validation of the interfaces and illustrating their potential for optimization. This work provides first insight into previously undiscovered oligomeric interactions between antibodies, and enables new opportunities for their biotherapeutic optimization.

Legend

Protein

Chemical

Disease

Primary Citation of related structures